New Publication That Supports Positive Results
NBS' new article published by the International Scholarly Research Network provides … further evidence that AMR-001 appears capable of preserving heart muscle function following a large myocardial infarction.
Amorcyte demonstrated in its P1 trial that AMR-001 preserved heart muscle function when a therapeutic dose of cells was administered. No patient experienced deterioration in heart muscle function who received 10 million cells or more whereas 30 to 40 percent of patients not receiving a therapeutic dose did.
The article titled "Assessment of myocardial contractile function using global and segmental circumferential strain following intracoronary stem cell infusion after myocardial infarction: MRI Feature Tracking Feasibility Study" by Sabha Bhatti, MD, et al. appears in ISRN Radiology Volume 2013, Article ID371028 and is published online at www.isrn.com/journals/radiology/2013/371028.
The Bottom Line: The new study shows that cardiac muscle function sparing effects are evident even earlier after treatment than previously shown. AMR-001 improved blood flow to the heart and preserved heart muscle. By using cardiac magnetic resonance imaging, specifically measuring circumferential strain of the left ventricle, the authors show that AMR-001′s effects are evident by 3 months after STEMI. AMR-001′s angiogenic and anti-apoptotic mechanisms of action indicate that preservation of heart muscle function should start within weeks and be evident in fewer than 6 months. This publication, based on blinded analysis of Amorcyte's P1 data, confirms the expected time course for AMR-001′s mechanism of action.
NBS closed 10/9 at $0.70 which was down from 10/8 by $0.03. NBS should be more positive < I project back to $0.73> today although markets are again projected lower.
Disclosure: I have no positions in any stocks mentioned, and no plans to initiate any positions within the next 72 hours.